cobimetinib
MMRF Data Fuels Greater Understanding of Multiple Myeloma Drug Resistance, Mutational Landscape
Premium
The nonprofit hopes its longitudinal studies and clinical trials will help move targeted therapies into upfront therapy for multiple myeloma.
High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds
Premium
UCSD and Fore Bio researchers found that patients harboring certain RAS mutations with high MAPK activity may benefit from treatment like Novartis' Mekinist.
FDA Approves Genentech's Tecentriq, Cotellic, Zelboraf for BRAF V600-Mutated Melanoma
The approval is based on the results from the Phase III IMspire150 study, in which patients treated with the three-drug combination had an improvement in progression-free survival.
AACR Studies in BRAF-Mutated Melanoma Show Benefit of Combo Treatment, Continuous Dosing Strategies
In two studies, researchers showed the benefit of combining Tecentriq, Cotellic, and Zelboraf and sticking with continuous versus intermittent dosing of targeted drugs.
InxMed Doses First Patient in Phase IB Trial of FAK Inhibitor for NRAS-Mutated Melanoma
The study will evaluate the effects of investigational drug IN10018 as a monotherapy and in combination with a MEK inhibitor.